Fierce Drug Dev Forum 2019 has ended
avatar for Chris Garabedian

Chris Garabedian

Chairman and CEO
Chris Garabedian is an industry pioneer with over two decades guiding and building early-stage biopharma companies ensuring development success.  Chris founded Xontogeny to support promising technologies from early development through clinical POC and formed a partnership with Perceptive Advisors to establish the firm’s venture fund strategy. As a member of the Perceptive Investment Team, Chris helps source, identify and fund venture opportunities as part of the Xontogeny portfolio and beyond. Chris has a broad base of experience and a track record of industry success across his career, including Gilead and Celgene. Most recently, Chris served as CEO of Sarepta Therapeutics, leading the development of the Duchenne Muscular Dystrophy program and overseeing its turnaround into a leader in the genetic technology space. Chris is on the BOD of MassBio, on the BOA for the Keck Graduate Institute and is a Senior Advisor for Boston Consulting Group.

My Speakers Sessions

Monday, October 28

4:00pm PDT